Please try another search
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Yong Liu | 49 | 2019 | CEO, GM & Chairman of the Board |
Feng Gao | 61 | 2021 | Independent Non-Executive Director |
Ranting Qian | 47 | 2021 | Supervisor |
Hongbin Zhou | 50 | 2020 | Non-Executive Director |
Houwei Hu | - | 2023 | Non-Executive Director |
Weiwei Qiao | 36 | 2021 | Chairman of the Supervisory Board |
Jiaxin Zhang | - | 2023 | Non-Executive Director |
Ming Fai Yuen | 73 | 2021 | Independent Non-Executive Director |
Ping Liu | 44 | 2022 | Employee Representative Supervisor |
Guodong Liang | 71 | 2021 | Independent Non-Executive Director |
Feizhou Wang | 56 | 2022 | Supervisor |
Lijun Xia | 47 | 2021 | Independent Non-Executive Director |
Jianping Chen | 46 | 2019 | Vice GM & Executive Director |
Kunxue Hong | 59 | 2021 | Chief Scientist & Non-Executive Director |
Bu Li | 47 | 2021 | Vice GM & Executive Director |
Qingqing Chen | 41 | 2021 | Vice GM, CFO, Secretary & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review